FDA advisory committee votes down single-arm studies for PI3K inhibitor approval

FDA’s ODAC to discuss the regulatory pathway for PI3K inhibitors this week

Plus Hillhouse-backed Overland finds CTO in Xun Liu, and updates from Veracyte, Janux, Connect and more

Created to house programs spun out from Merck KGaA and CRUK, iOnctura prepares for first-in-human studies